🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. CAR-T Re-treatment

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  2. CAR-T cell infusion

    The First People's Hospital of Lianyungang

    Hematolymphoid Malignancies

    phase 1 small molecule active

    1 trial

  3. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  4. CD-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  5. CD19-STAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B Cell Malignancy

    phase 1 mab completed

    1 trial

  6. CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory B-cell Malignancies

    phase 1 mab active

    1 trial

  7. CLN-049

    Cullinan Therapeutics

    Relapsed/Refractory Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  8. CLN-617

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  9. CLN-619

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  10. CLN-619

    Cullinan Therapeutics

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  11. CLN-978

    Cullinan Therapeutics

    NHL

    phase 1 small molecule active

    1 trial

  12. CLN-978

    Cullinan Therapeutics

    Rheumatoid Arthritis (RA

    phase 1 small molecule active

    1 trial

  13. CLN-978

    Cullinan Therapeutics

    Sjögren

    phase 1 small molecule active

    1 trial

  14. CLN-978

    Cullinan Therapeutics

    SLE

    phase 1 small molecule active

    1 trial

  15. CMP-001

    Regeneron UK Limited

    Malignant Melanoma

    phase 1 small molecule completed

    1 trial

  16. CNTY-101

    Century Therapeutics

    R/R CD19-Positive B-Cell Malignancies

    phase 1 mab terminated

    1 trial

  17. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Hematologic Malignancy

    phase 1 small molecule completed

    1 trial

  18. Cemiplimab

    Regeneron UK Limited

    Advanced Malignancies

    phase 1 small molecule active

    1 trial

  19. Ceralasertib

    AstraZeneca

    Advanced Solid Malignancies

    phase 1 small molecule completed

    1 trial

  20. Ciforadenant

    Corvus Pharmaceuticals

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  21. Ciforadenant

    Corvus Pharmaceuticals

    Renal Cell Cancer

    phase 1 small molecule completed

    1 trial

  22. Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  23. Comparative Bioavailability of Levonorgestrel 52 mg Intrauterine System versus Mirena® in Healthy Pre-Menopausal, Non-Pregnant Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  24. DEB025

    ENANTA PHARMACEUTICALS INC

    Hepatitis C Virus

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources